Serum Paraoxonase-1 Concentration as a Potential Predictor of Urinary Bladder Cancer Recurrence. A Five Year Follow-Up Study

Archives of Medical Research

Volumn 49, Issue 2, 2018, Pages 119-122

  Iftimie, Simona ^a   García Heredia, Anabel ^a   Pujol Bosch, Francesc ^a   Pont Salvadó, Antoni ^a   López Azcona, Ana Felisa ^a   Hernández Aguilera, Anna ^a   Cabré, Noemí ^a   Luciano Mateo, Fedra ^a   Fort Gallifa, Isabel ^a   Castro, Antoni ^a   Camps, Jordi ^a   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Biomarkers; Paraoxonase 1; Tumor recurrence; Urinary bladder cancer

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCALCITONIN; ARYLDIALKYLPHOSPHATASE; GAMMA CHEMOKINE; PON1 PROTEIN, HUMAN; TUMOR MARKER; XCL2 PROTEIN, HUMAN;

ARTICLE; BLADDER CANCER; CATHETER INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; MALE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; BLADDER TUMOR; BLOOD;

ARYLDIALKYLPHOSPHATASE; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; CHEMOKINES, C; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROCALCITONIN; ROC CURVE; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 85046130249     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2018.04.011     Document Type: Article

References (22)

1. Galceran, J., Ameijide, A., Carulla, M., et al. Cancer incidence in Spain. Clin Transl Oncol 2017:19 (2015), 799–825.
2. Alfred Witjes, J., Lebret, T., Compérat, E.M., et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71 (2017), 462–475.
3. Bacchetti, T., Ferretti, G., Sahebkar, A., The role of paraoxonase in cancer. Semin Cancer Biol, 2017 pii:S1044–S1579X(17)30191–30198.
4. Pla, A., Rodrigo, L., Hernández, A.F., et al. Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem Biol Interact 167 (2007), 63–70.
5. Camps, J., Marsillach, J., Joven, J., The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 46 (2009), 83–106.
6. Bobin-Dubigeon, C., Lefrançois, A., Classe, J.M., et al. Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence. Clin Biochem 48 (2015), 1181–1183.
7. Iftimie, S., García-Heredia, A., Pujol, I., et al. Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria. Eur J Clin Microbiol Infect Dis 35 (2016), 1417–1424.
8. Marsillach, J., Aragonès, G., Beltrán, R., et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin Biochem 42 (2009), 91–98.
9. Marsillach, J., Mackness, B., Mackness, M., et al. Immunochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med 45 (2008), 146–157.
10. Marsillach, J., Aragonès, G., Mackness, B., et al. Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis, 9, 2010, 46.
11. Zweig, M.H., Campbell, G., Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39 (1993), 561–577.
12. Kitchen, M.O., Bryan, R.T., Emes, R.D., et al. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. Epigenetics 11 (2016), 237–246.
13. Arenas, M., García-Heredia, A., Gascon, M., et al. Paraoxonase-1 activity and concentration after radiation therapy treatment in patients with breast cancer: Can be a useful marker to predict the radiation therapy toxicity and breast cancer prognosis?. Int J Radiat Oncol Biol Phys, 93, 2016, E517.
14. Utanğaç, M.M., Yeni, E., Savaş, M., et al. Paraoxonase and arylesterase activity in bladder cancer. Turk J Urol 43 (2017), 147–151.
15. Shariat, S.F., Karam, J.A., Lotan, Y., et al. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10 (2008), 120–135.
16. Goodison, S., Chang, M., Dai, Y., et al. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One, 7, 2012, e47469.
17. Karaoglu, I., van der Heijden, A.G., Witjes, J.A., The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle-invasive bladder cancer. World J Urol 32 (2014), 651–659.
18. de Martino, M., Shariat, S.F., Hofbauer, S.L., et al. Aurora A kinase as a diagnostic urinary marker for urothelial bladder cancer. World J Urol 33 (2015), 105–110.
19. Wang, J., Zhang, X., Wei, P., et al. Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer. World J Urol 32 (2014), 1477–1484.
20. Todenhöfer, T., Hennenlotter, J., Guttenberg, P., et al. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. BMC Cancer, 15, 2015, 155.
21. Nagata, M., Muto, S., Horie, S., Molecular Biomarkers in Bladder Cancer: Novel potential indicators of prognosis and treatment outcomes. Dis Markers, 2016, 2016, 8205836.
22. Zheng, L.F., Sun, W.Y., Meta-analysis of microRNAs as biomarkers for muscle-invasive bladder cancer. Biomed Rep 5 (2016), 159–164.